• Je něco špatně v tomto záznamu ?

Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges

MC. Mir, L. Albiges, A. Bex, M. Hora, G. Giannarini, A. Volpe, M. Rouprêt, EAU Section of Oncological Urology (ESOU) Board

. 2021 ; 4 (5) : 843-850. [pub] 20200615

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012139

This case presents a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma (RCC) with multiple bone lesions. The patient underwent a single resection of skull bone lesion (diagnostic for poorly differentiated carcinoma of unknown origin) and cytoreductive nephrectomy. The pathology of the kidney specimen demonstrated an oncocytic papillary RCC. Within 3 mo, she developed skeletal progressive disease and was started on systemic therapy (sunitinib). After initial stabilization, bone metastasis progressed during the third cycle of sunitinib and required second-line therapy (cabozantinib). One of the major unmet needs in non-clear cell RCC is the lack of specific systemic therapy. Data on immunotherapy are still limited. Inclusion of these patients in clinical trials is strongly recommended. PATIENT SUMMARY: Patients with metastatic kidney cancer who present with the less common histological subtype (non-clear cell) have poor survival. In this case, the patient responded to second-line therapy. Very few therapies provide response to treatment. Patients should be offered participation in clinical trials testing combinations with immunotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012139
003      
CZ-PrNML
005      
20220506131523.0
007      
ta
008      
220425s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2020.05.010 $2 doi
035    __
$a (PubMed)32553707
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mir, Maria Carmen $u Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain. Electronic address: mirmare@yahoo.es
245    10
$a Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges / $c MC. Mir, L. Albiges, A. Bex, M. Hora, G. Giannarini, A. Volpe, M. Rouprêt, EAU Section of Oncological Urology (ESOU) Board
520    9_
$a This case presents a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma (RCC) with multiple bone lesions. The patient underwent a single resection of skull bone lesion (diagnostic for poorly differentiated carcinoma of unknown origin) and cytoreductive nephrectomy. The pathology of the kidney specimen demonstrated an oncocytic papillary RCC. Within 3 mo, she developed skeletal progressive disease and was started on systemic therapy (sunitinib). After initial stabilization, bone metastasis progressed during the third cycle of sunitinib and required second-line therapy (cabozantinib). One of the major unmet needs in non-clear cell RCC is the lack of specific systemic therapy. Data on immunotherapy are still limited. Inclusion of these patients in clinical trials is strongly recommended. PATIENT SUMMARY: Patients with metastatic kidney cancer who present with the less common histological subtype (non-clear cell) have poor survival. In this case, the patient responded to second-line therapy. Very few therapies provide response to treatment. Patients should be offered participation in clinical trials testing combinations with immunotherapy.
650    12
$a karcinom z renálních buněk $x farmakoterapie $x chirurgie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $7 D007668
650    12
$a nádory ledvin $x farmakoterapie $x chirurgie $7 D007680
650    _2
$a nefrektomie $7 D009392
650    _2
$a sunitinib $x terapeutické užití $7 D000077210
655    _2
$a časopisecké články $7 D016428
700    1_
$a Albiges, Laurence $u Medical Oncology, Gustave Roussy, Universite Paris-Saclay, Villejuif, France
700    1_
$a Bex, Axel $u The Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Hora, Milan $u Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
700    1_
$a Giannarini, Gianluca $u Urology Unit, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy
700    1_
$a Volpe, Alessandro $u Division of Urology, Department of Translational Medicine, Maggiore della Carita Hospital, University of Eastern Piedmont, Novara, Italy
700    1_
$a Rouprêt, Morgan $u Predictive onco-uro, APHP, Urology, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
710    2_
$a EAU Section of Oncological Urology (ESOU) Board
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 4, č. 5 (2021), s. 843-850
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32553707 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131515 $b ABA008
999    __
$a ok $b bmc $g 1789643 $s 1163340
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 4 $c 5 $d 843-850 $e 20200615 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
LZP    __
$a Pubmed-20220425
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace